BIIB News and Press, Biogen Inc. From 03/14/24

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB). Investors who purchased Biogen Inc. securities are encouraged to obtain additional informat...

2024-03-14 07:20:30 ET More on WuXi AppTec, WuXi AppTec, etc. Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family WuXi Biologics: Recent Share Price Recovery Isn't Sustainable Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppT...

2024-03-11 13:07:11 ET More on S&P 500 Index: Japan's Q4 '23 Contraction Revised Away, Helping Keep Yen Bid S&P 500: 'Everything' Is Overbought, Not Just Semis And Nvidia S&P 500: A Significant Change - Week Starting 11th March (Technical Analysis) ...

2024-03-11 12:23:20 ET More on AbCellera, Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) AbCellera: Victim Of Its Own Success AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript Biogen Alzheimer’s drug...

2024-03-07 09:59:39 ET More on Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen grant...

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most part...

New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from...

2024-03-02 04:53:00 ET On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen , (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311. One driver for that anticipated growth is the company's newl...

2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...

2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...